ЗОМЕТА В КОМПЛЕКСНОМ ЛЕЧЕНИИ ГЕНЕРАЛИЗОВАННОГО РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ: КЛИНИЧЕСКОЕ НАБЛЮДЕНИЕ
https://doi.org/10.17650/1994-4098-2009-0-1-2-41-43
Аннотация
Список литературы
1. Coleman R.E. Skeletal complications of malignancy. Cancer 1997;80:1588—94.
2. Lipton A. Theriault R.L., Hortobaggyi G.N. et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases. Long term follow-up of two randomized, placebo-controlled tri- als. Cancer 2000;88:1082—90.
3. Kanis J.A., McCloskey E.V. Bone turnover and biochemical markers in malignancy. Cancer 1997;80(8):1691—5.
4. Fleisch H. Bisphosphonates in bone disease — from the laboratory to the patient. New York: The Parthenon Publishing Group, 1997.
5. Mundy G.R. Preclinical studies of metastases: experimental models and novel techniques to detect micrometastases. In: Program and abstracts of 22nd San Antonio Breast Cancer Symposium; 1999.
6. Senaratne W.G., Pirianov G., Mansi J.L. et al. Bisphosphonates induce apoptosis in human breast cancer cell lines. Br J Cancer 2000;82:1459—68.
7. Hiraga T., Williams P.J., Ueda A. et al. Zoledronic acid inhibits visceral metas- tases in the 4T1/luc mouse breast cancer model. Clin Cancer Res ;10:4559—67.
Рецензия
Для цитирования:
Болотина Л.В. ЗОМЕТА В КОМПЛЕКСНОМ ЛЕЧЕНИИ ГЕНЕРАЛИЗОВАННОГО РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ: КЛИНИЧЕСКОЕ НАБЛЮДЕНИЕ. Опухоли женской репродуктивной системы. 2009;(1-2):41-43. https://doi.org/10.17650/1994-4098-2009-0-1-2-41-43
For citation:
Bolotina L.V. ZOMETA IN COMPLEX TREATMENT FOR GENERALIZED BREAST CANCER: A CLINICAL CASE. Tumors of female reproductive system. 2009;(1-2):41-43. (In Russ.) https://doi.org/10.17650/1994-4098-2009-0-1-2-41-43